Trial Profile

Phase II Study of Targeting CD28 in Multiple Myeloma With Abatacept (CTLA4-Ig) to Overcome Resistance to Chemotherapy

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 06 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abatacept (Primary) ; Abatacept (Primary) ; Dexamethasone (Primary) ; Ixazomib (Primary)
Indications Multiple myeloma
Focus Therapeutic Use

Most Recent Events

04 Mar 2025 Status changed from active, no longer recruiting to discontinued. Reason the study was stopped: funding ended.
04 Feb 2024 Planned End Date changed from 11 Jan 2024 to 11 Jan 2025.
13 Nov 2023 Planned End Date changed from 11 Nov 2023 to 11 Jan 2024.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com